Hepatitis-B virus infection in India: Findings from a nationally representative serosurvey, 2017-18.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Murhekar Manoj V, Santhosh Kumar Muthusamy, Kamaraj P, Khan Siraj Ahmed, Allam Ramesh Reddy, Barde Pradip, Dwibedi Bhagirathi, Kanungo Suman, Mohan Uday, Mohanty Suman Sundar, Roy Subarna, Sagar Vivek, Savargaonkar Deepali, Tandale Babasaheb V, Topno Roshan Kamal, Girish Kumar C P, Sabarinathan R, Bitragunta Sailaja, Grover Gagandeep Singh, Lakshmi P V M, Mishra Chandra Mauli, Sadhukhan Provash, Sahoo Prakash Kumar, Singh S K, Yadav Chander Prakash, Kumar Rajesh, Dutta Shanta, Toteja G S, Gupta Nivedita, Mehendale Sanjay M, ICMR – Serosurvey group
Аннотация
METHODS: We tested sera from 8273 children for different markers of HB infection and estimated weighted age-group specific seroprevalence of children who were chronically infected (HBsAg and anti-HBc positive), and immune due to past infection (anti-HBc positive and HBsAg negative), and having serological evidence of HB vaccination (only anti-HBs positive). We compared the prevalence of serological markers among children born before (aged 11-17 years) and after (aged 5-10 years) introduction of HB-vaccine from phase-1 states.
RESULTS: Among children aged 5-8 years, 1.1% were chronic carriers, 5.3% immune due to past infection, and 23.2% vaccinated. The corresponding proportions among children aged 9-17 years were 1.1%, 8.0%, and 12.0%, respectively. In phase-1 states, children aged 5-10 years had a significantly lower prevalence of anti-HBc (4.9% vs. 7.6%, p<0.001) and higher prevalence of anti-HBs (37.7% vs. 14.7%, p<0.001) compared to children aged 11-17 years. HBsAg positivity, however, was not different in the two age groups.
CONCLUSIONS: Children born after the introduction of HB vaccination had a lower prevalence of past HBV infection and a higher prevalence of anti-HBs. The findings of our study could be considered as an interim assessment of the impact of the hepatitis B vaccine introduction in India.